Current through Register Vol. 51, No. 3, September 1, 2024
RELATES TO: KRS Chapter 342
NECESSITY, FUNCTION, AND CONFORMITY:
KRS
342.035 requires the commissioner to
promulgate administrative regulations to establish a schedule of fees for the
purpose of ensuring that all fees, charges, and reimbursements under
KRS
342.020 shall be fair, current, reasonable,
and limited to that paid for similar treatment of other patients in the same
community.
KRS
342.035(1) authorizes the
commissioner to consider the increased security of payment afforded by KRS
Chapter 342 in determining what constitutes a reasonable fee.
KRS
342.735 requires the commissioner to
establish administrative regulations to expedite the payment of medical expense
benefits. This administrative regulation establishes charges for
pharmaceuticals provided pursuant to
KRS
342.020 and expedites the payment of this
class of medical expense benefits.
Section
1. Definitions.
(1) "Brand drug"
means a drug product identified as a brand by Medi-span or any other drug
product commercially available from only one (1) source.
(2) "Compound" is defined by
803 KAR
25:270, Section 1(3).
(3) "Equivalent drug product" is defined by
KRS
217.814(5).
(4) "Generic drug" means a drug that is not a
brand drug..
(5) "Hospital" is
defined by
803 KAR
25:091, Section 1(1).
(6) "Medical payment obligor" is defined by
803 KAR
25:260, Section 1(10).
(7) "Medical provider" is defined by 803 KAR
25:260(11).
(8) "NDC number" means
the unique eleven (11) digit, three (3) segment, number assigned to a drug
product and maintained in the NDC Directory published by the U.S. Food and Drug
Administration.
(9) "Pharmacist" is
defined by
803 KAR
25:270, Section 1(15).
(10) "Pharmacy benefit manager" means an
entity licensed pursuant to
KRS
304.9-053 that, on behalf of a medical
payment obligor:
(a) Contracts directly or
indirectly with pharmacies to provide prescription drugs to
individuals;
(b) Administers a
prescription drug benefit;
(c)
Processes or pays pharmacy claims;
(d) Makes or assists in making prior
authorization determinations on prescription drugs; or
(e) Establishes a pharmacy network.
(11) "Prescription drug" is
defined by
803 KAR
25:270, Section 1(18).
(12) "Repackage" means the act of taking a
finished drug product from the container in which it was distributed by the
original manufacturer and placing it into a different container without further
manipulation of the drug.
(13)
"Usual and customary" means the charge a provider would apply to an otherwise
uninsured patient.
Section
2. Payment for Pharmaceuticals.
(1) Reimbursement shall be determined on the
date of service. The maximum allowable reimbursement for prescription drugs
shall be a dispensing fee of five (5) dollars and the lesser of:
(a) The provider's usual and customary charge
for the drug;
(b) If it is a
generic drug, eighty-five (85) percent of the average wholesale price of the
lowest priced equivalent drug product; or
(c) If it is a brand drug, ninety (90)
percent of average wholesale price.
(2) Average wholesale price shall be
determined from the publication in effect on the date of service. The
publication to be used shall be:
(a)
Medi-Span, produced by Wolters-Kluwer; or
(b) If the drug is not included in Medi-Span,
then the Red Book, produced by Micromedex, shall be used.
(3) The usual and customary charge of the
provider for the prescription drug shall be included on each statement for
services.
(4) A generic drug shall
be substituted for a brand drug unless there is no equivalent drug product
available or the prescribing medical provider indicates on the prescription
that substitutions are prohibited.
(5) If a claimant chooses a brand drug and a
generic drug is available and allowed by the medical provider, the claimant
shall pay the difference in price between the brand and the generic drug as
determined pursuant to subsection (1) of this section.
(6) A dispensing provider that is not a
pharmacist shall be reimbursed the same as a pharmacist, but shall not receive
a dispensing fee.
(7) Repackaged or
Compounded Drugs
(a) Pharmaceutical bills
submitted for repackaged or compounded drugs shall include the NDC Number of
the original manufacturer registered with the U.S. Food and Drug
Administration.
(b) Reimbursement
shall be determined using the original manufacturer's NDC number for the
product or ingredient, calculated on a per unit basis, as of the date of
service. The maximum reimbursement limitations established in subsection (1) of
this section shall apply to each product or ingredient contained in the
repackaged or compounded drug.
(c)
An NDC number obtained for a repackaged or compounded drug shall not be
considered the original manufacturer's NDC Number.
(d) If the original manufacturer's NDC Number
is not provided on the bill, then the reimbursement shall be based on the
average wholesale price of the lowest priced equivalent drug product,
calculated on a per unit basis.
(e)
A single compounding fee of twenty (20) dollars shall be reimbursed for a
compounded drug.
Section
3. Disputes; Applicability.
(1)
Any dispute arising under this administrative regulation may be resolved
pursuant to
803 KAR
25:012 or
803 KAR
25:110, Section 10.
(2) This administrative regulation shall
apply to prescriptions dispensed to a workers' compensation patient by a
hospital pharmacy if the patient is not otherwise being treated or obtaining
medical care from the hospital.
(3)
This administrative regulation shall not apply to prescriptions dispensed by a
hospital pharmacy, of a hospital regulated pursuant to
803 KAR
25:091, to a workers' compensation patient receiving
medical treatment or care from the hospital on an inpatient or outpatient
basis.
(4) Any insurance carrier,
self-insured employer, group self-insured employer, or pharmacy benefit manager
may enter into an agreement with any pharmacy or other provider to provide
reimbursement at a lower amount than that required in this administrative
regulation.
Section 4.
Balance Billing.
(1) A pharmacy filling a
prescription covered under
KRS
342.020 shall not knowingly collect, attempt
to collect, coerce, or attempt to coerce, directly or indirectly, the payment
by a workers' compensation patient of any charge in excess of that permitted
under this administrative regulation, except as established in Section 2(2) of
this administrative regulation.
(2)
This prohibition shall be applicable to prescriptions filled pursuant to
KRS
342.020 and any prescription denied or
disputed by the medical payment obligor may be billed directly to the party
presenting the prescription for filling.
STATUTORY AUTHORITY:
KRS
342.020,
342.035,
342.260,
342.270,
342.735